Literature DB >> 8471334

Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population.

T Aareleid1, E Pukkala, H Thomson, M Hakama.   

Abstract

Long term trends in the incidence of and mortality from invasive cervical cancer have been studied in Finland (1953-1987) and Estonia (1968-1987). The analyses are based on the data from the Finnish and Estonian Cancer Registries. An organised nationwide screening programme for cervical cancer was started in Finland in the early 1960s. In Estonia, no cytological screening programme has been introduced, and cervical malignancies are diagnosed in routine gynaecological practice. During 1968-1987, both the incidence of and mortality from cervical cancer were considerably higher in Estonia than in Finland. A decrease has taken place in the cervical cancer incidence and mortality in both countries since the mid-1960s, but whereas in Finland the decrease has been marked, in Estonia it has been less pronounced and levelled off in the 1980s. In 1987, the age-standardised (world population) incidence rate per 100,000 women was 14.0 in Estonia and 3.8 in Finland, and the age-standardised mortality rate was 6.0 and 1.6 per 100,000, respectively. The difference in the incidence of the disease in the two neighbouring countries can be partially attributed to socioeconomic factors. The main reason for the different slopes of the trend curves for cervical cancer is probably the difference in public health policies: an effective mass screening programme is being conducted in Finland but not in Estonia.

Entities:  

Mesh:

Year:  1993        PMID: 8471334     DOI: 10.1016/s0959-8049(05)80359-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Increase in cervical cancer mortality in Spain, 1951-1991.

Authors:  J Llorca; M D Prieto; M Delgado-Rodríguez
Journal:  J Epidemiol Community Health       Date:  1999-07       Impact factor: 3.710

Review 2.  Cost-effective policies for cervical cancer screening. An international review.

Authors:  M C Fahs; S B Plichta; J S Mandelblatt
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

3.  Effects of screening on cervical cancer incidence and mortality in New South Wales implied by influences of period of diagnosis and birth cohort.

Authors:  R J Taylor; S L Morrell; H A Mamoon; G V Wain
Journal:  J Epidemiol Community Health       Date:  2001-11       Impact factor: 3.710

4.  Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.

Authors:  Rebecca B Perkins; Sarah M Langrish; Linda J Stern; James F Burgess; Carol J Simon
Journal:  Womens Health Issues       Date:  2009-11-26

5.  Incidence and mortality of gynaecological cancers: Secular trends in urban Shanghai, China over 40 years.

Authors:  Zhezhou Huang; Ying Zheng; Wanqing Wen; Chunxiao Wu; Pingping Bao; Chunfang Wang; Weijian Zhong; Yu-Tang Gao; Fan Jin; Yong-Bing Xiang; Xiao-Ou Shu; Alicia Beeghly-Fadiel
Journal:  Eur J Cancer       Date:  2016-05-26       Impact factor: 9.162

6.  Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.

Authors:  K J Sales; A A Katz; M Davis; S Hinz; R P Soeters; M D Hofmeyr; R P Millar; H N Jabbour
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

7.  Cervical cancer screening in primary health care setting in Sudan: a comparative study of visual inspection with acetic acid and Pap smear.

Authors:  Ahmed Ibrahim; Arja R Aro; Vibeke Rasch; Eero Pukkala
Journal:  Int J Womens Health       Date:  2012-02-28

8.  Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.

Authors:  Mari Nygård; Anne-Kjersti Daltveit; Steinar O Thoresen; Jan F Nygård
Journal:  BMC Health Serv Res       Date:  2007-01-23       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.